Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Role of spironolactone chalcone in the prevention of peritoneal fibrosis in patients with peritoneal dialysis

Liang Han¹, Xiao-Dong Yang²

¹Department of Nephrology; ²Department of Endocrine, Zhumadian Center Hospital, Zhumadian 463000, China.

For correspondence:- Xiao-Dong Yang Email: yangxiaodong04@gmail.com Tel:+863962726207

Received: 19 May 2015 Accepted: 29 August 2015 Published: 31 October 2015

Citation: Han L, Yang X. Role of spironolactone chalcone in the prevention of peritoneal fibrosis in patients with peritoneal dialysis. Trop J Pharm Res 2015; 14(10):1893-1897 doi: 10.4314/tjpr.v14i10.22

© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: The study was designed to investigate the effects of a novel spironolactone chalcone in the prevention of peritoneal fibrosis.

Methods: Wistar rats (n = 30) were randomly assigned to 3 groups: bacteria (B), spironolactone amide treatment (S), and control (C) groups. C group received only dextran beads while S and B groups were given bacteria and dextran beads intraperitoneally, but spironolactone chalcone was also given to S group. The treatments were administered daily. The rats were sacrificed on day 15 to quantify peritoneal adhesion and for histological examination of the peritoneal tissues using hematoxylin, eosin and Masson’s trichrome dyes. Enzyme-linked immunosorbent assay (ELISA) kit was used to determine TGFβ1 content of peritoneal fluids and serum samples.

Results: Spironolactone chalcone treatment at a dose of 30 mg/kg body weight daily for 15 days significantly reduced peritoneal total adhesion score in S group compared to untreated B group (p < 0.01). S group also showed significantly lower mean peritoneal thickness, inflammation score, and fibrosis score compared to B group. Serum transforming growth factor β1 was also reduced significantly in S group animals on spironolactone chalcone treatment compared to B group.

Conclusion: Spironolactone chalcone is a potentially effective candidate for decreasing the extent of peritoneal injury caused by bacterial peritonitis.

Keywords: Peritoneal thickness, Inflammation score, Adhesion score, Bacterial peritonitis, Peritoneal fluids